DCCT/EDIC Research Group: Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: Long-term follow-up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study. Lancet Diabetes Endocrinol 2014; 2:793–800.

• PubMed
DCCT/EDIC Research Group: Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: Long-term follow-up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study. Lancet Diabetes Endocrinol 2014; 2:793–800.)| false
• Search Google Scholar
• Export Citation

Zoungas S , et al.. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med 2014; 371:1392–1406.

• PubMed
Zoungas S , . Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med 2014; 371:1392–1406.)| false
• Search Google Scholar
• Export Citation

Perkovic V , et al.. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int 2013; 83:517–523.

• PubMed
Perkovic V , . Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int 2013; 83:517–523.)| false
• Search Google Scholar
• Export Citation

Lewis EJ , et al.. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329:1456–1462.

• PubMed
Lewis EJ , . The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329:1456–1462.)| false
• Search Google Scholar
• Export Citation

Fried LF , et al.. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013; 369:1892–1903.

• PubMed
Fried LF , . Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013; 369:1892–1903.)| false
• Search Google Scholar
• Export Citation

Perkovic V , et al.. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380:2295–2306.

• PubMed
Perkovic V , . Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380:2295–2306.)| false
• Search Google Scholar
• Export Citation

Chan GC and Tang SC . Diabetic nephropathy: Landmark clinical trials and tribulations. Nephrol Dial Transplant 2016; 31:359–368.

• PubMed
Chan GC and Tang SC . Diabetic nephropathy: Landmark clinical trials and tribulations. Nephrol Dial Transplant 2016; 31:359–368.)| false
• Search Google Scholar
• Export Citation

Diabetes Control and Complications Trial Research Group, et al.. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329:977–986.

• PubMed
Diabetes Control and Complications Trial Research Group, . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329:977–986.)| false
• Search Google Scholar
• Export Citation

DCCT/EDIC Research Group. Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: Long-term follow-up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study. Lancet Diabetes Endocrinol 2014; 2:793–800.

• PubMed
DCCT/EDIC Research Group. Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: Long-term follow-up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study. Lancet Diabetes Endocrinol 2014; 2:793–800.)| false
• Search Google Scholar
• Export Citation

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:837–853.

• PubMed
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:837–853.)| false
• Search Google Scholar
• Export Citation

Perkovic V , et al.. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int 2013; 83:517–523.

• PubMed
Perkovic V , . Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int 2013; 83:517–523.)| false
• Search Google Scholar
• Export Citation

Action to Control Cardiovascular Risk in Diabetes Study, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358:2545–2559.

• PubMed
Action to Control Cardiovascular Risk in Diabetes Study, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358:2545–2559.)| false
• Search Google Scholar
• Export Citation

Lewis EJ , et al.. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329:1456–1462.

• PubMed
Lewis EJ , . The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329:1456–1462.)| false
• Search Google Scholar
• Export Citation

Brenner BM , et al.. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861–869.

• PubMed
Brenner BM , . Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861–869.)| false
• Search Google Scholar
• Export Citation

Lewis EJ , et al.. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851–860.

• PubMed
Lewis EJ , . Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851–860.)| false
• Search Google Scholar
• Export Citation

Haller H , et al.. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011; 364:907–917.

• PubMed
Haller H , . Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011; 364:907–917.)| false
• Search Google Scholar
• Export Citation

Mann JF , et al.. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372:547–553.

• PubMed
Mann JF , . Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372:547–553.)| false
• Search Google Scholar
• Export Citation

Fried LF , et al.. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013; 369:1892–1903.

• PubMed
Fried LF , . Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013; 369:1892–1903.)| false
• Search Google Scholar
• Export Citation

Parving HH , et al.. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; 367:2204–2213.

• PubMed
Parving HH , . Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; 367:2204–2213.)| false
• Search Google Scholar
• Export Citation

de Zeeuw D , et al.. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med 2013; 369:2492–2503.

• PubMed
de Zeeuw D , . Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med 2013; 369:2492–2503.)| false
• Search Google Scholar
• Export Citation

Mann JF , et al.. Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 2010; 21:527–535.

• PubMed
Mann JF , . Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 2010; 21:527–535.)| false
• Search Google Scholar
• Export Citation

Perkovic V , et al.. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380:2295–2306.

• PubMed
Perkovic V , . Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380:2295–2306.)| false
• Search Google Scholar
• Export Citation